Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
September 16, 2024 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
September 13, 2024 09:05 ET
|
Outlook Therapeutics, Inc.
Webcast replay of fireside chat now available ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory...
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
September 04, 2024 08:35 ET
|
Outlook Therapeutics, Inc.
Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved...
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:45 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
August 14, 2024 07:05 ET
|
Outlook Therapeutics, Inc.
Received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMDNORSE EIGHT current enrollment pace supports topline readout...
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 12, 2024 09:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™...
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
August 07, 2024 08:35 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized...
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
July 30, 2024 09:10 ET
|
Outlook Therapeutics, Inc.
Company to participate in a fireside chat on Monday, August 5th at 8:00 AM ET ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company...
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
July 08, 2024 08:35 ET
|
Outlook Therapeutics, Inc.
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMDInitial commercial launches of...
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
June 11, 2024 09:05 ET
|
Outlook Therapeutics, Inc.
Live video webcast on Tuesday, June 18th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the...